Advertisement

Topics

U.S. DOD to Start New Trial with Pluristem's PLX-R18 Cell Therapy Against ARS

02:06 EDT 17 Aug 2017 | Genetic Engineering News

The U.S. Department of Defense’s (DOD) Armed Forces Radiobiology Research Institute (AFRRI) is to undertake a pilot study in non-human primates (NHP) evaluating Pluristem Therapeutics’ PLX-R18 as a treatment for acute radiation syndrome (ARS) prior to and within the first 24 hours of radiation exposure. The AFRRI is part of the Uniformed Services University of Health Sciences (USU). Pluristem’s PLX-R18 is an off-the-shelf placental expanded (PLX) cell therapy product generated from placenta-derived mesenchymal-like adherent stromal cells. The cells are designed to release a combination of therapeutic proteins to help treat bone marrow that has been damaged due to ARS, or as a result of cancer, cancer therapy, or immune-mediated bone marrow failure. Last month Pluristem reported positive data from an ongoing Phase II-equivalent NHP trial carried out by the National Institute of Allergy and Infectious Diseases (NIAID), which also investigated PLX-R18 cells as a treatment for ARS. ...

Original Article: U.S. DOD to Start New Trial with Pluristem's PLX-R18 Cell Therapy Against ARS

NEXT ARTICLE

More From BioPortfolio on "U.S. DOD to Start New Trial with Pluristem's PLX-R18 Cell Therapy Against ARS"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...